Workflow
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
GlobeNewswire· 2025-05-12 20:00
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders, today announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May. Presentation Details American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting Title:Evaluation of MERTK gene therapy ...
Oxford Lane Capital Corp. Schedules Fourth Fiscal Quarter Earnings Release and Conference Call for May 19, 2025
GlobeNewswire· 2025-05-12 20:00
GREENWICH, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) announced today that it will hold a conference call to discuss its fourth fiscal quarter earnings on Monday, May 19, 2025 at 9:00 AM ET. The toll-free dial-in number is 1-833-470-1428, access code number 818188. There will be a recorded replay of the call available for 30 days after the call ...
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire· 2025-05-12 20:00
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis. NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- ...
Gabelli Funds to Host 17th Annual Media & Entertainment Symposium Thursday, June 5, 2025
GlobeNewswire· 2025-05-12 20:00
GREENWICH, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Media & Entertainment Symposium at the Harvard Club in New York City on Thursday, June 5, 2025. The symposium will feature discussions with leading companies and organizations across the media ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Sports Investing, Media & Telecom Regulatory, and Advertising Panels. Attendees will also have the opportunity to meet with ...
Longevity Health Holdings, Inc. Announces Reverse Stock Split
GlobeNewswire· 2025-05-12 20:00
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with ...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire· 2025-05-12 20:00
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, ...
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire· 2025-05-12 20:00
ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusionWARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today annou ...
ProStar and JAVAD GNSS Announce a Global Partnership to Deliver Precision Mapping Technology to the Utility Industry
GlobeNewswire· 2025-05-12 19:58
GRAND JUNCTION, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- ProStar® Holdings Inc., (“ProStar®” or “the Company”) (TSXV: MAPS, OTCQX: MAPPF, FSE: 5D00), the developer of the PointMan® Precision Mapping Solutions®, and JAVAD GNSS, the manufacturer of patented GNSS technologies, have partnered to bring JAVAD GNSS receivers to the utility and critical infrastructure industry. This collaboration is the latest in ProStar’s ongoing strategy to integrate the world’s best-in-class technologies into its PointMan solutio ...
LNG Energy Group Announces Cease Trade Order
GlobeNewswire· 2025-05-12 19:49
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- LNG Energy Group Corp. (TSXV: LNGE) (TSXV: LNGE.WT) (OTCQB: LNGNF) (FWB: E26) (the “Company” or “LNG Energy Group”) announces that, further to the news release dated May 7, 2025, the Ontario Securities Commission (the “OSC”), has notified the Company that it has issued a failure-to-file cease trade order (“FFCTO”), under Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions against the Company (“MI 11-103”). The FFCTO was issu ...
Neinor completes strategic monetization of BTR portfolio, unlocking c.€325mn since 2023
GlobeNewswire· 2025-05-12 19:46
DELTA RENTAL HOMES DELTA RENTAL HOMES Neinor Homes has sold five rental buildings, totalling 251 housing units for c.€50mn Since 2023, Neinor Homes has sold a total of 1,334 rental units, for c.€325mn with an attractive gross development margin of 24.8% After this disposal, Neinor has successfully concluded its objective to fully crystallize the value of its rental portfolio Including figures from 1Q25, Neinor pre-sold a total of 921 housing units in its strongest ever start of the year MADRID ...